Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02763319
Recruitment Status : Active, not recruiting
First Posted : May 5, 2016
Last Update Posted : June 10, 2021
Sponsor:
Collaborator:
ICON Clinical Research
Information provided by (Responsible Party):
MorphoSys AG

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : March 2022
Estimated Study Completion Date : March 2024